A substantial $280.0M has been secured by Idorsia Pharmaceuticals Ltd, the Swiss-headquartered biopharmaceutical company focused on discovering and developing innovative small molecule medicines.
This fresh capital is earmarked to accelerate Idorsia's mission to transform the horizon of therapeutic options, supporting its strategic goal of becoming a leading biopharmaceutical company with a strong scientific core. The company, based in Europe's biotech hub, emphasizes its commitment to bringing more ideas and opportunities to patients.
